Crossref
Analysing Survival Outcomes in Advanced Pancreatic Cancer: Benefit of Second and Later Line Therapy ‐ Real World Outcomes from the Australasian Purple Pancreatic Cancer Registry
Asia-Pacific Journal of Clinical Oncology · 2026-11 · 22 (S6) · 22-22
DOI: 10.1111/ajco.70237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.11.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Analysing Survival Outcomes in Advanced Pancreatic Cancer: Benefit of Second and Later Line Therapy ‐ Real World Outcomes from the Australasian Purple Pancreatic Cancer Registry. Asia-Pacific Journal of Clinical Oncology, 22(S6), 22-22. https://doi.org/10.1111/ajco.70237
Vancouver
Analysing Survival Outcomes in Advanced Pancreatic Cancer: Benefit of Second and Later Line Therapy ‐ Real World Outcomes from the Australasian Purple Pancreatic Cancer Registry. Asia-Pacific Journal of Clinical Oncology. 2026;22(S6):22-22. doi:10.1111/ajco.70237
BibTeX
@article{euvimed2026,
title = {Analysing Survival Outcomes in Advanced Pancreatic Cancer: Benefit of Second and Later Line Therapy ‐ Real World Outcomes from the Australasian Purple Pancreatic Cancer Registry},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {S6},
pages = {22--22},
doi = {10.1111/ajco.70237}
}
EUVIMED